Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

evinacumab

Sanofi reception

Solid start for Dupixent as Sanofi raises 2017 outlook

Analysts predict dermatology medicine could become a €5bn product if approved in other indications

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

Sanofi reception

Sanofi and Regeneron bag EU approval for arthritis drug Kevzara

The IL-6 inhibitor will be used in combination with methotrexate for adults with RA

Sanofi reception

Sanofi/Regeneron’s Sarilumab cleared by FDA on second attempt

IL-6 inhibitor to treat adult RA patients

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

- PMLiVE

Amgen sues Sanofi and Regeneron over eczema drug

Alleges patent infringement and seeks financial reparations

- PMLiVE

Regeneron bags US approval for eczema drug Dupixent

Aims to balance affordability and rewarding innovation with the treatment's pricing

- PMLiVE

GSK and Regeneron tap into UK Biobank resource

Data collection project for genetic sequencing could deliver vital data within the next year

Sanofi reception

Sanofi adds to dupilumab evidence base as US approval nears

FDA to deliver verdict on atopic dermatitis drug

Sanofi reception

Praluent can stay on market for now, says US court

Sanofi and Regeneron win appeal to suspended permanent injunction sought by Amgen

Sanofi reception

Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Competition to Roche’s blockbuster RA therapy heats up as Canada is first to licence new drug

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links